Artwork

Sisällön tarjoaa David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.
Player FM - Podcast-sovellus
Siirry offline-tilaan Player FM avulla!

52: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 2

25:41
 
Jaa
 

Manage episode 417264496 series 3525243
Sisällön tarjoaa David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Does the process of commercializing cell and gene therapies seem complex and unclear to you?

Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therapies to patients.

From cutting-edge technologies to innovative collaboration models, we explore the future landscape of these transformative treatments.

You’ll get:

  1. An understanding of how partnerships between academic centers, pharma companies, and regulators can decrease development costs and simplify commercialization, resulting in wider accessibility.
  2. An investigation into how data analytics, AI, and machine learning can transform supply chains, target selection, commercialization strategies, and regulatory frameworks.
  3. A discovery of new methods for equitable therapy access, such as outcome-based pricing, local manufacturing, and the growing role of digital platforms in patient advocacy.

Join us on this insightful journey into the future of cell and gene therapies.

Connect with Wajiha Ali:

LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454

X (Twitter): https://twitter.com/Wajihaali

Next Step:

Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

  continue reading

59 jaksoa

Artwork
iconJaa
 
Manage episode 417264496 series 3525243
Sisällön tarjoaa David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado. David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado, David Brühlmann: Biotech Entrepreneur, and Cell Culture Technology Innovation Aficionado tai sen podcast-alustan kumppani lataa ja toimittaa kaiken podcast-sisällön, mukaan lukien jaksot, grafiikat ja podcast-kuvaukset. Jos uskot jonkun käyttävän tekijänoikeudella suojattua teostasi ilman lupaasi, voit seurata tässä https://fi.player.fm/legal kuvattua prosessia.

Does the process of commercializing cell and gene therapies seem complex and unclear to you?

Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therapies to patients.

From cutting-edge technologies to innovative collaboration models, we explore the future landscape of these transformative treatments.

You’ll get:

  1. An understanding of how partnerships between academic centers, pharma companies, and regulators can decrease development costs and simplify commercialization, resulting in wider accessibility.
  2. An investigation into how data analytics, AI, and machine learning can transform supply chains, target selection, commercialization strategies, and regulatory frameworks.
  3. A discovery of new methods for equitable therapy access, such as outcome-based pricing, local manufacturing, and the growing role of digital platforms in patient advocacy.

Join us on this insightful journey into the future of cell and gene therapies.

Connect with Wajiha Ali:

LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454

X (Twitter): https://twitter.com/Wajihaali

Next Step:

Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

  continue reading

59 jaksoa

Kaikki jaksot

×
 
Loading …

Tervetuloa Player FM:n!

Player FM skannaa verkkoa löytääkseen korkealaatuisia podcasteja, joista voit nauttia juuri nyt. Se on paras podcast-sovellus ja toimii Androidilla, iPhonela, ja verkossa. Rekisteröidy sykronoidaksesi tilaukset laitteiden välillä.

 

Pikakäyttöopas